Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
Status:
Completed
Trial end date:
2017-05-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to try to find out how critically ill patients receiving the
anti fungal medication, posaconazole, process it in their body. Investigators would like to
study if the recommended doses of posaconazole achieve adequate concentrations in the
patients blood to treat fungal infections.The disease process in critically ill patients can
profoundly influence the concentration of anti fungal medication in the blood. The process by
which a drug travels through the body in blood, how it is broken down and removed by the body
is called pharmacokinetics (PK).
This information is important to know because if antifungal levels are low in the blood, the
fungal infection has an opportunity to become resistant to the antifungal medication which
can lead to the medication being less effective against the fungal infection potentially
exposing future patients with infection to a limited range of effective antifungals.
Investigators can measure the PK by taking blood samples at specific times after the anti
fungal medication is given.
This study will enroll 8 patients who are admitted to the intensive care unit and are being
treated with an antifungal medication for a fungal infection. Patients will be consented and
given a single dose of posaconazole and serial blood samples will be collected just prior to
the dose and at 15, 45,75 minutes during the infusion and at 3, 5, 8, 12, 18, 24, 30 36 and
48 hours . Information about the patients stay in the ICU will also be collected including
blood pressure, temperature, blood test results.